Oct 6, 2026 07:30AM
Oct 6, 2026 07:30AM
Sep 28, 2026 07:30AM
Sep 28, 2026 07:30AM
Sep 22, 2026 08:01AM
Sep 22, 2026 08:00AM
Aug 10, 2026 04:30PM SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jul 31, 2026 12:07PM
Jun 30, 2026 08:02AM
Jun 30, 2026 08:00AM
May 11, 2026 04:23PM
Mar 31, 2026 07:06AM
Mar 31, 2026 06:40AM
Mar 31, 2026 06:40AM SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar 4, 2026 04:20PM
Feb 26, 2026 08:23AM
Feb 26, 2026 08:23AM
Jan 28, 2026 08:00AM
Jan 21, 2026 08:01AM
Jan 21, 2026 08:00AM
Dec 22, 2025 08:02AM SCYNEXIS receives 180-day Nasdaq extension until June 15, 2026
Dec 22, 2025 08:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 10:16AM
Nov 17, 2025 10:15AM
Nov 5, 2025 04:20PM
Oct 28, 2025 07:14AM
Oct 15, 2025 08:01AM SCYNEXIS receives $22 million from GSK to resolve MARIO study dispute
Oct 15, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 4, 2025 08:30AM
Aug 25, 2025 08:00AM
Aug 13, 2025 04:30PM
May 28, 2025 08:31AM Scynexis (SCYX) resumes dosing in Phase 3 study of ibrexafungerp
May 28, 2025 08:30AM
May 15, 2025 04:20PM
Apr 8, 2025 08:05AM
Apr 8, 2025 08:00AM
Mar 12, 2025 05:08PM
Dec 18, 2024 08:00AM
Nov 6, 2024 04:30PM SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 10, 2024 08:00AM
Oct 3, 2024 08:00AM
Aug 27, 2024 08:00AM
Aug 8, 2024 04:30PM
Jul 23, 2024 07:02AM
Jul 23, 2024 07:00AM
May 8, 2024 04:30PM SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30, 2024 04:05PM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All